Can You Still Get Chemo If You Have a Cold?

Chemotherapy can sometimes proceed even when you have a cold, but often it gets delayed. The decision depends on your blood counts, the severity of your symptoms, and which chemotherapy drugs you’re receiving. Your oncology team will typically run blood work before each session, and what those numbers show matters more than whether you have the sniffles. A mild runny nose with normal white blood cell counts might not stop treatment, but a cold with fever, low neutrophils, or chest congestion usually will.

Why a Cold Matters More During Chemotherapy

Most chemotherapy drugs suppress bone marrow function, which means your body produces fewer white blood cells, the immune cells that fight off infections. When those counts drop low enough, even an ordinary cold virus can escalate into something serious. Respiratory viral infections in cancer patients increase both the risk of complications and the chance that chemotherapy will be postponed.¹ The concern is not just the cold itself but the domino effect: your immune system is already compromised, the virus strains it further, and adding another round of marrow-suppressing drugs on top of that can push you into dangerous territory.

The key number your doctor watches is your absolute neutrophil count (ANC). Neutrophils are the white blood cells that serve as your front line against bacterial and fungal infections. When they fall very low, a condition called neutropenia, your risk of developing a fever with neutropenia (febrile neutropenia) climbs sharply. In one study of breast cancer patients receiving adjuvant chemotherapy, those whose neutrophil counts dropped to very low levels after the first cycle had a febrile neutropenia rate of about 30%, compared with roughly 10% in patients whose counts stayed higher.² Adding a viral infection to an already low count makes febrile neutropenia even more likely.

How the Decision Gets Made on Treatment Day

When you show up for a scheduled infusion with cold symptoms, the process usually follows a predictable sequence. A nurse or physician will check your temperature, review your symptoms, and order a complete blood count. If your ANC is above a safe threshold and your symptoms are limited to mild congestion or a runny nose without fever, many oncologists will proceed with treatment. If your temperature is elevated, if your ANC is low, or if you have symptoms that suggest the infection has moved into your chest, treatment is typically postponed.

Part of the challenge for the medical team is distinguishing a genuine infection from side effects of the chemo itself. Some chemotherapy drugs cause fever on their own. One study found that fever appeared within the first 12 hours of treatment with certain agents like cytarabine in nearly half of cases, and with dacarbazine in about 16% of cases. In those instances, inflammatory markers stayed in the normal range and the patients’ physical exams were unremarkable, confirming the fever was drug-related rather than infectious.³ But when you arrive already running a fever before the drugs go in, that picture flips: the medical team needs to rule out an active infection before proceeding.

Molecular diagnostic tests have improved the ability to identify respiratory viruses quickly. Multiplex panels can now detect a broad range of viruses from a single nasal swab, which has led to many more respiratory infections being caught in cancer patients than were recognized in earlier decades.⁴ That improved detection is a double-edged sword: it catches infections early enough to intervene, but it also means more treatment delays when a virus is identified that might have gone unnoticed before.

When Treatment Gets Delayed and What That Means for Outcomes

Getting treatment postponed because of a cold is understandably stressful. If you’re in the middle of a multi-cycle regimen, you worry that the delay gives the cancer time to regroup. The evidence on this is nuanced and depends on how long the delay lasts.

Short delays of a week or so generally do not meaningfully affect prognosis. A study of ovarian cancer patients found that delays of less than a month produced survival outcomes virtually identical to finishing chemotherapy on schedule, with a median overall survival of about 44.5 months compared with 43.1 months for the on-time group. Longer delays, however, were a different story: patients with extended treatment gaps survived a median of roughly 18 months, far worse than those who stayed on schedule.⁵ The pattern held for progression-free survival as well.

In early-stage breast cancer, a retrospective study found that patients who experienced inter-cycle treatment delays had significantly lower survival probability, with a roughly 33% increase in the risk of death over five years compared with patients who stayed on schedule.⁶ It’s worth noting that in these studies, the patients who experienced delays often had more complications overall, so the delay itself may partly be a marker of sicker patients rather than the sole cause of worse outcomes. Still, the data reinforces why oncologists try to keep treatment on track when safely possible.

The takeaway for someone sitting at home with a stuffy nose and a chemo appointment in two days: a one-week postponement while you recover from a mild cold is unlikely to change your long-term outcome. Repeated or prolonged delays across several cycles are where the risk adds up. Your oncologist will weigh the risk of the delay against the risk of treating you while you’re fighting an infection, and in most cases a short pause is the safer bet.

What You Should Watch for Between Treatment Cycles

One of the tricky things about having a cold during chemo is figuring out when symptoms cross the line from “uncomfortable but manageable” to “call the doctor now.” Research into how patients with neutropenic sepsis experience their early symptoms found something concerning: nearly all patients understood they should call if they developed a fever, but very few recognized the significance of feeling generally unwell in the absence of a fever.⁷ In other words, people tended to fixate on the thermometer reading and overlook other warning signs.

Temperature is an important signal, but it’s not the only one. Symptoms worth reporting to your team even if you don’t have a fever include:

• New or worsening cough: Especially if it produces colored mucus, involves chest tightness, or comes with shortness of breath.
• Unusual fatigue or confusion: Feeling dramatically more wiped out than your baseline chemo fatigue, or having difficulty thinking clearly.
• Shaking chills: Rigors can signal a developing infection even before your temperature spikes.
• Sore throat with difficulty swallowing: Mucositis from chemo can cause mouth and throat sores, but new throat pain combined with cold symptoms could indicate a secondary infection.

The standard advice from most oncology teams is to call immediately if your temperature reaches 100.4°F (38°C) or higher. But given that many patients underestimate non-fever symptoms, a good rule of thumb is to call whenever something feels off enough that you’re debating whether to call. Oncology nurses field these calls constantly and would rather hear from you early than see you in the emergency department later.

Tools Your Doctor Has to Keep Treatment on Track

When cold-related delays threaten to push treatment significantly off schedule, oncologists have a few options beyond simply waiting. Growth factor injections, commonly referred to as G-CSF (granulocyte colony-stimulating factor), stimulate the bone marrow to produce neutrophils faster. A study of breast cancer patients who received a short course of G-CSF after chemotherapy found that none of the treated patients required hospitalization for febrile neutropenia, and the median dose intensity delivered was essentially 100% of the planned amount.⁸ These injections don’t treat the cold, but they can help your immune system recover faster so that treatment can resume sooner.

For the viral infection itself, the options are more limited. Unlike bacterial infections, most cold viruses don’t have targeted treatments. Influenza is an exception (antivirals like oseltamivir can shorten its course), and some newer antiviral options exist for other respiratory viruses in immunocompromised patients. Early diagnosis and supportive care have been shown to improve outcomes when respiratory viruses are caught in cancer patients.¹ For a typical rhinovirus cold, though, supportive care (rest, fluids, managing symptoms) is the main strategy.

Dose reduction is another lever. If your counts keep dipping low with each cycle and colds keep interrupting treatment, your oncologist might reduce the chemotherapy dose slightly to keep your immune system from bottoming out as severely. This is a trade-off, as lower doses might be slightly less effective against the cancer, but maintaining a consistent treatment schedule at a slightly lower dose can be better overall than full doses with long gaps between them.

Children Face Higher Risks from Respiratory Infections During Treatment

The interaction between colds and chemotherapy plays out differently in children, and the stakes tend to be higher. A study of children and adolescents with acute lymphoblastic leukemia found that about 43% developed viral respiratory illness during treatment. Among those who got sick, 80% had their chemotherapy delayed, about 61% were hospitalized, and roughly a quarter experienced a complicated disease course.⁹ The risk was highest during the induction phase of treatment, when chemotherapy is most intense and immune suppression is most severe.

That said, not every respiratory virus causes equal trouble. A study of pediatric cancer patients found that the clinical picture of many common respiratory viruses was relatively mild, without progression to lower respiratory tract infections in most cases.¹⁰ The problem is that doctors can’t always predict which children will sail through a cold and which will develop complications, so the threshold for delaying treatment or hospitalizing a child tends to be lower than for adults. Parents of children on chemotherapy often find themselves in a difficult spot: their child picks up a cold from a sibling or classmate, and suddenly the treatment calendar shifts. Pediatric oncology teams generally build some flexibility into treatment protocols for exactly this reason.

Reducing Your Chances of Getting Sick in the First Place

Prevention is worth more than treatment when your immune system is suppressed. The basics are well known: hand hygiene, avoiding crowded indoor spaces when possible, asking household members to stay home when they’re sick, and keeping up with recommended vaccinations (flu and COVID vaccines in particular, though your oncologist will advise on timing relative to your chemo cycles). Some cancer centers have experimented with more structured prevention programs. One study found that a nursing intervention combining infection control education with respiratory function training significantly reduced healthcare-associated infection rates in leukemia patients during chemotherapy.¹¹

Practical strategies that patients report finding helpful include wearing a well-fitted mask in waiting rooms and public transit, keeping a separate set of hand towels in the bathroom, and having a plan for isolating from sick family members when possible. None of this is foolproof, and living in a bubble isn’t realistic, especially over months of treatment. But each layer of protection you add reduces the odds that a cold virus will interrupt your treatment schedule.

When the Cold Might Not Actually Be a Cold

One complication that catches some patients off guard is that what feels like a cold might be something else entirely. Chemotherapy side effects can mimic cold symptoms: a runny nose from certain drugs, a cough from lung irritation, fatigue that gets mistaken for viral malaise. On the other side of the coin, an early bacterial infection can masquerade as a simple cold before it escalates. The inflammatory markers that normally signal a serious infection in a healthy person, such as a rising white blood cell count, may not behave predictably when chemo has already altered your blood counts.

This is where having a relationship with your oncology team pays off. They know your baseline. They know what your blood counts looked like at your last visit, which drugs you’re on, and what symptoms are typical for your regimen. A cough that would be unremarkable in someone who isn’t on treatment warrants at least a phone call when you’re mid-cycle. Many cancer centers now have 24-hour nurse lines specifically for patients in active treatment, and using them isn’t being paranoid. It’s being appropriately cautious given that your immune system is working with a smaller toolkit than usual.

If you do develop symptoms between cycles and your next infusion is days away, don’t wait until treatment day to mention it. Calling ahead gives your team time to order labs, adjust the schedule if needed, or bring you in for an evaluation before the situation becomes more complex. The patients who tend to do best during chemotherapy are the ones who communicate early and often, not the ones who tough it out and hope for the best.